Stay Up
to Date
Stay Up
to Date
Breaking News,
Updates, & More
Breaking News,
Updates, & More
Click Here to
Subscribe
Click Here to
Subscribe

Ovarian Cancer

Although many individuals with cancer are offered access to patient portals, only two-thirds take advantage of this service when it is offered. Recent data showed that individuals with newly diagnosed cancer viewed their own electronic health record more frequently than cancer survivors or individuals who did not have cancer. Additional studies are warranted to determine which factors influence patient portal use so that effective interventions can be developed to increase the use of this valuable technology.
When it comes to purchasing medical practice management software, information technology experts recommend certain features, including comprehensive appointment scheduling with automated appointment reminders, an online patient portal with secure messaging, and the ability to integrate with a practice’s electronic health record system.
In this exclusive interview, Melissa Paige, Chief Executive Officer and Founder, Paige Consulting, LLC, Charlottesville, VA, and Infusion/Oncology Patient Access Principal Coordinator at a large academic center, shares her experience in helping patients with cancer obtain access to oral and infused therapies.
Medically integrated dispensing models enhance oral oncology drug education and improve compliance and patient monitoring.
New model aims to ease transition from fee-for-service to value-based cancer care delivery using an oncology medical home framework and performance-based reimbursement that includes monthly care management payments.
Incident cases of ovarian cancer differed little between ever users and never users of powder with no dose-response relationship.
Although performance category weightings remain unchanged from 2019, the Centers for Medicare & Medicaid Services has raised the bar for participating providers by increasing the performance threshold from 30 to 45 points in 2020.
The use of combination therapies in the first- and second-line settings for advanced ovarian cancer has the potential to improve patient outcomes.
Although federal reform efforts are likely to stall in the Senate, legislation prohibiting gag clauses, claw backs, and price spreading are being passed at the state level.
Patients and healthcare providers should be aware of the toxicities that may occur with the use of PARP inhibitors so that they can manage them appropriately.
Page 1 of 3
Results 1 - 10 of 27